Base de dados : MEDLINE
Pesquisa : G12.450.573 [Categoria DeCS]
Referências encontradas : 6819 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 682 ir para página                         

  1 / 6819 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29360883
[Au] Autor:Rodrigues TC; Oliveira MLS; Soares-Schanoski A; Chavez-Rico SL; Figueiredo DB; Gonçalves VM; Ferreira DM; Kunda NK; Saleem IY; Miyaji EN
[Ad] Endereço:Laboratório de Bacteriologia, Instituto Butantan, São Paulo, SP, Brazil.
[Ti] Título:Mucosal immunization with PspA (Pneumococcal surface protein A)-adsorbed nanoparticles targeting the lungs for protection against pneumococcal infection.
[So] Source:PLoS One;13(1):e0191692, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Burden of pneumonia caused by Streptococcus pneumoniae remains high despite the availability of conjugate vaccines. Mucosal immunization targeting the lungs is an attractive alternative for the induction of local immune responses to improve protection against pneumonia. Our group had previously described the development of poly(glycerol adipate-co-ω-pentadecalactone) (PGA-co-PDL) polymeric nanoparticles (NPs) adsorbed with Pneumococcal surface protein A from clade 4 (PspA4Pro) within L-leucine microcarriers (nanocomposite microparticles-NCMPs) for mucosal delivery targeting the lungs (NP/NCMP PspA4Pro). NP/NCMP PspA4Pro was now used for immunization of mice. Inoculation of this formulation induced anti-PspA4Pro IgG antibodies in serum and lungs. Analysis of binding of serum IgG to intact bacteria showed efficient binding to bacteria expressing PspA from clades 3, 4 and 5 (family 2), but no binding to bacteria expressing PspA from clades 1 and 2 (family 1) was observed. Both mucosal immunization with NP/NCMP PspA4Pro and subcutaneous injection of the protein elicited partial protection against intranasal lethal pneumococcal challenge with a serotype 3 strain expressing PspA from clade 5 (PspA5). Although similar survival levels were observed for mucosal immunization with NP/NCMP PspA4Pro and subcutaneous immunization with purified protein, NP/NCMP PspA4Pro induced earlier control of the infection. Conversely, neither immunization with NP/NCMP PspA4Pro nor subcutaneous immunization with purified protein reduced bacterial burden in the lungs after challenge with a serotype 19F strain expressing PspA from clade 1 (PspA1). Mucosal immunization with NP/NCMP PspA4Pro targeting the lungs is thus able to induce local and systemic antibodies, conferring protection only against a strain expressing PspA from the homologous family 2.
[Mh] Termos MeSH primário: Proteínas de Bactérias/administração & dosagem
Imunidade nas Mucosas
Nanopartículas
Pneumonia Bacteriana/prevenção & controle
[Mh] Termos MeSH secundário: Adsorção
Animais
Líquido da Lavagem Broncoalveolar
Ensaio de Imunoadsorção Enzimática
Feminino
Imunofenotipagem
Camundongos
Camundongos Endogâmicos BALB C
Pneumonia Bacteriana/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Bacterial Proteins); 0 (pneumococcal surface protein A)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180124
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0191692


  2 / 6819 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27776452
[Au] Autor:Vo Ngoc DT; Krist L; van Overveld FJ; Rijkers GT
[Ad] Endereço:a Department of Science , University College Roosevelt , Middelburg , The Netherlands.
[Ti] Título:The long and winding road to IgA deficiency: causes and consequences.
[So] Source:Expert Rev Clin Immunol;13(4):371-382, 2017 04.
[Is] ISSN:1744-8409
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: The most common humoral immunodeficiency is IgA deficiency. One of the first papers addressing the cellular and molecular mechanisms underlying IgA deficiency indicated that immature IgA-positive B-lymphocytes are present in these patients. This suggests that the genetic background for IgA is still intact and that class switching can take place. At this moment, it cannot be ruled out that genetic as well as environmental factors are involved. Areas covered: A clinical presentation, the biological functions of IgA, and the management of IgA deficiency are reviewed. In some IgA deficient patients, a relationship with a loss-of-function mutation in the TACI (transmembrane activator and calcium-modulating cyclophilin ligand interaction) gene has been found. Many other genes also have been associated. Gut microbiota are an important environmental trigger for IgA synthesis. Expert commentary: Expression of IgA deficiency is due to both genetic and environmental factors and a role for gut microbiota cannot be excluded.
[Mh] Termos MeSH primário: Linfócitos B/fisiologia
Deficiência de IgA/imunologia
Imunidade nas Mucosas
Imunoglobulina A/metabolismo
Microbiota/imunologia
Células Precursoras de Linfócitos B/fisiologia
Proteína Transmembrana Ativadora e Interagente do CAML/genética
[Mh] Termos MeSH secundário: Animais
Fator Ativador de Células B/genética
Interação Gene-Ambiente
Predisposição Genética para Doença
Seres Humanos
Deficiência de IgA/etiologia
Switching de Imunoglobulina
Polimorfismo Genético
Membro 13 da Superfamília de Ligantes de Fatores de Necrose Tumoral/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (B-Cell Activating Factor); 0 (Immunoglobulin A); 0 (TNFRSF13B protein, human); 0 (Transmembrane Activator and CAML Interactor Protein); 0 (Tumor Necrosis Factor Ligand Superfamily Member 13)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:180215
[Lr] Data última revisão:
180215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161026
[St] Status:MEDLINE
[do] DOI:10.1080/1744666X.2017.1248410


  3 / 6819 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28466091
[Au] Autor:Li S; Sha Z; Wang X; Bu Z; Wang L; Guan X; Lang X; Wang X
[Ad] Endereço:Institute of Military Veterinary, Academy of Military Medical Sciences, Changchun, Jilin, China.
[Ti] Título:Yeast Surface Display of Escherichia coli Enterotoxin and Its Effects of Intestinal Microflora and Mucosal Immunity.
[So] Source:Curr Microbiol;74(7):854-862, 2017 Jul.
[Is] ISSN:1432-0991
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Enterotoxigenic Escherichia coli (ETEC) is a significant cause of infectious diarrhea in animals. In this study, yeast surface display technology was employed to investigate the effects of ETEC enterotoxin fusion protein on the intestinal flora and mucosal immunity of rats. ETEC estA, estB, and eltAB (heat-labile and heat-stable toxins) were expressed on the surface of yeast. Rats were divided into normal saline, yeast and display yeast groups. Fecal and jejunal content samples were collected on the 7th, 14th, and 21st days. Rats were then fed ETEC for 3 days before again collecting these samples. Levels of SIgA, IL-2, IL-4, IFN-γ, and microbial population density and diversity were documented by ELISA, T-RFLP and real-time PCR. The results demonstrated that estA, estB, and eltAB fusion proteins were expressed on the surface of yeast. Following ETEC challenge, levels of SIgA, IL-2, IL-4, IFN-γ, and, the numbers and variety of intestinal microbes were significantly increased in rats receiving display yeast and yeast. These factors were significantly decreased in rats given normal saline and yeast. Our results indicate that display yeast and yeast can increase the number and diversity of intestinal microbes in rats and improve intestinal immune function. After ETEC challenge, the display yeast can better maintain the balance of intestinal bacteria and mucosal immunity.
[Mh] Termos MeSH primário: Toxinas Bacterianas/genética
Enterotoxinas/genética
Infecções por Escherichia coli/microbiologia
Escherichia coli/genética
Microbioma Gastrointestinal
Expressão Gênica
Imunidade nas Mucosas
Intestinos/microbiologia
Saccharomyces cerevisiae/genética
[Mh] Termos MeSH secundário: Animais
Toxinas Bacterianas/imunologia
Enterotoxinas/metabolismo
Escherichia coli/metabolismo
Infecções por Escherichia coli/imunologia
Seres Humanos
Intestinos/imunologia
Ratos
Ratos Sprague-Dawley
Saccharomyces cerevisiae/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Bacterial Toxins); 0 (Enterotoxins)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180212
[Lr] Data última revisão:
180212
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170504
[St] Status:MEDLINE
[do] DOI:10.1007/s00284-017-1259-1


  4 / 6819 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29326275
[Au] Autor:Leonardi I; Li X; Semon A; Li D; Doron I; Putzel G; Bar A; Prieto D; Rescigno M; McGovern DPB; Pla J; Iliev ID
[Ad] Endereço:Gastroenterology and Hepatology Division, Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York, NY 10021, USA.
[Ti] Título:CX3CR1 mononuclear phagocytes control immunity to intestinal fungi.
[So] Source:Science;359(6372):232-236, 2018 01 12.
[Is] ISSN:1095-9203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Intestinal fungi are an important component of the microbiota, and recent studies have unveiled their potential in modulating host immune homeostasis and inflammatory disease. Nonetheless, the mechanisms governing immunity to gut fungal communities (mycobiota) remain unknown. We identified CX3CR1 mononuclear phagocytes (MNPs) as being essential for the initiation of innate and adaptive immune responses to intestinal fungi. CX3CR1 MNPs express antifungal receptors and activate antifungal responses in a Syk-dependent manner. Genetic ablation of CX3CR1 MNPs in mice led to changes in gut fungal communities and to severe colitis that was rescued by antifungal treatment. In Crohn's disease patients, a missense mutation in the gene encoding CX3CR1 was identified and found to be associated with impaired antifungal responses. These results unravel a role of CX3CR1 MNPs in mediating interactions between intestinal mycobiota and host immunity at steady state and during inflammatory disease.
[Mh] Termos MeSH primário: Receptor 1 de Quimiocina CX3C/análise
Receptor 1 de Quimiocina CX3C/genética
Candida albicans/imunologia
Microbioma Gastrointestinal/imunologia
Intestinos/microbiologia
Micobioma/imunologia
Fagócitos/imunologia
[Mh] Termos MeSH secundário: Animais
Anticorpos Antifúngicos/biossíntese
Anticorpos Antifúngicos/sangue
Candida albicans/crescimento & desenvolvimento
Colite/tratamento farmacológico
Colite/microbiologia
Doença de Crohn/genética
Doença de Crohn/imunologia
Células Dendríticas/imunologia
Microbioma Gastrointestinal/fisiologia
Seres Humanos
Imunidade nas Mucosas
Imunoglobulina G/biossíntese
Imunoglobulina G/sangue
Intestinos/imunologia
Camundongos
Mutação de Sentido Incorreto
Micobioma/fisiologia
Fagócitos/microbiologia
Linfócitos T Reguladores/imunologia
Células Th17/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Nm] Nome de substância:
0 (Antibodies, Fungal); 0 (CX3C Chemokine Receptor 1); 0 (CX3CR1 protein, human); 0 (Cx3cr1 protein, mouse); 0 (Immunoglobulin G)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180210
[Lr] Data última revisão:
180210
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180113
[St] Status:MEDLINE
[do] DOI:10.1126/science.aao1503


  5 / 6819 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27771185
[Au] Autor:Habets MN; van Selm S; van Opzeeland FJ; Simonetti E; Hermans PWM; de Jonge MI; Diavatopoulos DA
[Ad] Endereço:Laboratory of Pediatric Infectious Diseases, Radboud Center for Infectious Diseases, Radboud University Medical Center, Geert Grooteplein 10 (Route 412), P.O. Box 9101, 6500 HB Nijmegen, The Netherlands.
[Ti] Título:Role of antibodies and IL17-mediated immunity in protection against pneumococcal otitis media.
[So] Source:Vaccine;34(48):5968-5974, 2016 11 21.
[Is] ISSN:1873-2518
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Widespread vaccination against Streptococcus pneumoniae (the pneumococcus) has significantly reduced pneumococcal disease caused by vaccine serotypes. Despite vaccination, overall pneumococcal colonization rates in children have not reduced and otitis media (OM) by non-vaccine serotypes remains one of the most common childhood infections. Pneumococcal surface protein A (PspA) has been shown to be a promising protein antigen to induce broad protection against pneumococcal colonization. However, its ability to protect against OM remains unclear. Using our previously established mouse model of influenza-virus induced pneumococcal OM, we here show that intranasal vaccination of mice with PspA together with the mucosal adjuvant CTB results in a decrease in pneumococcal load in the middle ears. This decrease correlated with the induction of PspA-specific IgA, a balanced IgG1:IgG2a antibody response and the induction of a mucosal Th17 response. Our data suggests that the IL-17 response to PspA is more important for protection against OM, whilst the presence of antibodies may be less important, as determined in mice deficient in IL-17 signaling or antibody production. Together, these results suggest that mucosal vaccination with PspA may not only protect against colonization, but also against the development of virus-induced pneumococcal OM.
[Mh] Termos MeSH primário: Anticorpos Antibacterianos/imunologia
Interleucina-17/imunologia
Otite Média/imunologia
Otite Média/prevenção & controle
Infecções Pneumocócicas/imunologia
Vacinas Pneumocócicas/imunologia
[Mh] Termos MeSH secundário: Adjuvantes Imunológicos/administração & dosagem
Administração Intranasal
Animais
Anticorpos Antibacterianos/sangue
Carga Bacteriana
Proteínas de Bactérias/imunologia
Modelos Animais de Doenças
Orelha Média/microbiologia
Imunidade nas Mucosas
Imunoglobulina A/imunologia
Interleucina-17/deficiência
Camundongos Endogâmicos BALB C
Otite Média/virologia
Infecções Pneumocócicas/microbiologia
Infecções Pneumocócicas/prevenção & controle
Vacinas Pneumocócicas/administração & dosagem
Streptococcus pneumoniae/imunologia
Streptococcus pneumoniae/isolamento & purificação
Células Th17/imunologia
Vacinação/métodos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Adjuvants, Immunologic); 0 (Antibodies, Bacterial); 0 (Bacterial Proteins); 0 (Immunoglobulin A); 0 (Interleukin-17); 0 (Pneumococcal Vaccines); 0 (pneumococcal surface protein A)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:180206
[Lr] Data última revisão:
180206
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE


  6 / 6819 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28463882
[Au] Autor:Kim CJ; Rousseau R; Huibner S; Kovacs C; Benko E; Shahabi K; Kandel G; Ostrowski M; Kaul R
[Ad] Endereço:aUniversity Health Network bDepartments of Medicine and Immunology, University of Toronto cMaple Leaf Medical Clinic dSt. Michael's Hospital, Toronto, Ontario, Canada.
[Ti] Título:Impact of intensified antiretroviral therapy during early HIV infection on gut immunology and inflammatory blood biomarkers.
[So] Source:AIDS;31(11):1529-1534, 2017 Jul 17.
[Is] ISSN:1473-5571
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Standard antiretroviral therapy (ART) is slow to reverse gut mucosal immune defects that cause persistent inflammation and immune activation. We examined whether intensifying early-administered ART through the addition of maraviroc and raltegravir would accelerate their resolution. DESIGN: ART-naïve men with early HIV infection were randomized in a double-blind manner to receive ART (emtricitabine/tenofovir disoproxil fumarate + lopinavir/ritonavir), together with either combined placebo or raltegravir + maraviroc, for 48 weeks. In a predefined substudy, paired blood and sigmoid biopsies were collected at baseline and week 48. Mucosal CD4 T-cell immune subsets (Th1, Th17, and Th22 cells), CD8 T-cell immune activation, and soluble blood markers of inflammation (IL-6, IL-17, macrophage inflammatory protein-1b, soluble CD14, and IL-10) and coagulation (D-dimer) were measured. RESULTS: A total of 22 participants were enrolled, a median of 4 months after HIV acquisition. At baseline, there was substantial systemic and mucosal immune activation, and gut CD4 T-cell numbers, Th22 cell numbers, and Th17 cell function were reduced compared with controls. Early ART restored gut Th22 numbers, improved but did not restore overall CD4 numbers, and had no impact on Th17 function. Plasma levels of soluble CD14 and D-dimer normalized, whereas other inflammatory cytokines were reduced but not normalized. ART intensification had no impact on any blood or gut immune parameters. CONCLUSION: Early HIV infection causes substantial mucosal and systemic immune activation, and gut CD4 T-cell dysfunction. One year of ART improved but did not normalize most parameters, regardless of intensification with raltegravir and maraviroc, and did not restore mucosal Th17 function.
[Mh] Termos MeSH primário: Fármacos Anti-HIV/farmacologia
Infecções por HIV/tratamento farmacológico
Imunidade nas Mucosas/efeitos dos fármacos
Inflamação/sangue
Inflamação/tratamento farmacológico
Mucosa Intestinal/efeitos dos fármacos
Mucosa Intestinal/imunologia
[Mh] Termos MeSH secundário: Adulto
Biomarcadores/sangue
Canadá
Cicloexanos/farmacologia
Método Duplo-Cego
Quimioterapia Combinada
Produtos de Degradação da Fibrina e do Fibrinogênio/efeitos dos fármacos
Citometria de Fluxo
Infecções por HIV/sangue
Infecções por HIV/imunologia
Seres Humanos
Inflamação/imunologia
Ativação Linfocitária/efeitos dos fármacos
Masculino
Meia-Idade
Estudos Prospectivos
Raltegravir Potássico/farmacologia
Células Th17/efeitos dos fármacos
Resultado do Tratamento
Triazóis/farmacologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anti-HIV Agents); 0 (Biomarkers); 0 (Cyclohexanes); 0 (Fibrin Fibrinogen Degradation Products); 0 (Triazoles); 0 (fibrin fragment D); 43Y000U234 (Raltegravir Potassium); MD6P741W8A (maraviroc)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180202
[Lr] Data última revisão:
180202
[Sb] Subgrupo de revista:IM; X
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE
[do] DOI:10.1097/QAD.0000000000001515


  7 / 6819 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29262351
[Au] Autor:Cao W; Kayama H; Chen ML; Delmas A; Sun A; Kim SY; Rangarajan ES; McKevitt K; Beck AP; Jackson CB; Crynen G; Oikonomopoulos A; Lacey PN; Martinez GJ; Izard T; Lorenz RG; Rodriguez-Palacios A; Cominelli F; Abreu MT; Hommes DW; Koralov SB; Takeda K; Sundrud MS
[Ad] Endereço:Department of Immunology and Microbiology, The Scripps Research Institute, Jupiter, FL 33458, USA.
[Ti] Título:The Xenobiotic Transporter Mdr1 Enforces T Cell Homeostasis in the Presence of Intestinal Bile Acids.
[So] Source:Immunity;47(6):1182-1196.e10, 2017 Dec 19.
[Is] ISSN:1097-4180
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:CD4 T cells are tightly regulated by microbiota in the intestine, but whether intestinal T cells interface with host-derived metabolites is less clear. Here, we show that CD4 T effector (Teff) cells upregulated the xenobiotic transporter, Mdr1, in the ileum to maintain homeostasis in the presence of bile acids. Whereas wild-type Teff cells upregulated Mdr1 in the ileum, those lacking Mdr1 displayed mucosal dysfunction and induced Crohn's disease-like ileitis following transfer into Rag1 hosts. Mdr1 mitigated oxidative stress and enforced homeostasis in Teff cells exposed to conjugated bile acids (CBAs), a class of liver-derived emulsifying agents that actively circulate through the ileal mucosa. Blocking ileal CBA reabsorption in transferred Rag1 mice restored Mdr1-deficient Teff cell homeostasis and attenuated ileitis. Further, a subset of ileal Crohn's disease patients displayed MDR1 loss of function. Together, these results suggest that coordinated interaction between mucosal Teff cells and CBAs in the ileum regulate intestinal immune homeostasis.
[Mh] Termos MeSH primário: Membro 1 da Subfamília B de Cassetes de Ligação de ATP/imunologia
Ácidos e Sais Biliares/imunologia
Linfócitos T CD4-Positivos/imunologia
Doença de Crohn/imunologia
Ileíte/imunologia
Mucosa Intestinal/imunologia
[Mh] Termos MeSH secundário: Membro 1 da Subfamília B de Cassetes de Ligação de ATP/deficiência
Membro 1 da Subfamília B de Cassetes de Ligação de ATP/genética
Acridinas/farmacologia
Adulto
Animais
Ácidos e Sais Biliares/metabolismo
Ácidos e Sais Biliares/farmacologia
Transporte Biológico
Linfócitos T CD4-Positivos/efeitos dos fármacos
Linfócitos T CD4-Positivos/patologia
Doença de Crohn/genética
Doença de Crohn/patologia
Modelos Animais de Doenças
Feminino
Regulação da Expressão Gênica
Proteínas de Homeodomínio/genética
Proteínas de Homeodomínio/imunologia
Homeostase/imunologia
Seres Humanos
Ileíte/genética
Ileíte/patologia
Íleo/imunologia
Íleo/patologia
Imunidade nas Mucosas
Mucosa Intestinal/patologia
Masculino
Camundongos
Camundongos Endogâmicos C57BL
Camundongos Transgênicos
Meia-Idade
Estresse Oxidativo
Transdução de Sinais
Tetra-Hidroisoquinolinas/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (ATP-Binding Cassette, Sub-Family B, Member 1); 0 (Acridines); 0 (Bile Acids and Salts); 0 (Homeodomain Proteins); 0 (Tetrahydroisoquinolines); 128559-51-3 (RAG-1 protein); N488540F94 (Elacridar)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:180109
[Lr] Data última revisão:
180109
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171221
[St] Status:MEDLINE


  8 / 6819 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29176760
[Au] Autor:Bruxelle JF; Mizrahi A; Hoÿs S; Collignon A; Janoir C; Péchiné S
[Ad] Endereço:EA4043 Unité Bactéries Pathogènes et Santé (UBaPS), Univ. Paris-Sud, Université Paris-Saclay, Châtenay-Malabry Cedex, France.
[Ti] Título:Clostridium difficile flagellin FliC: Evaluation as adjuvant and use in a mucosal vaccine against Clostridium difficile.
[So] Source:PLoS One;12(11):e0187212, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The immunogenicity of bacterial flagellin has been reported in different studies. By its close interaction with the immune system, the flagellin represents an interesting adjuvant and vaccine candidate. Salmonella Typhimurium flagellin has already been tested as adjuvant to stimulate mucosal immunity. Here, we assessed the ability of Clostridium difficile flagellin FliC to act as a mucosal adjuvant, first combined with ovalbumin as antigen and second with a C. difficile surface protein, the precursor of the S-layer proteins SlpA. Using ovalbumin as antigen, we compared the gut mucosal adjuvanticity of FliC to Salmonella Typhimurium flagellin and cholera toxin. Two routes of immunization were tested in a mouse model: intra-rectal and intra-peritoneal, following which, gut mucosal and systemic antibody responses against ovalbumin (Immunoglobulins G and Immunoglobulins A) were analyzed by Enzyme-Linked Immuno Assay in intestinal contents and in sera. In addition, ovalbumin-specific immunoglobulin producing cells were detected in the intestinal lamina propria by Enzyme-Linked Immunospot. Results showed that FliC as adjuvant for immunization targeting ovalbumin was able to stimulate a gut mucosal and systemic antibody response independently of the immunization route. In order to develop a mucosal vaccine to prevent C. difficile intestinal colonization, we assessed in a mouse model the efficacy of FliC as adjuvant compared with cholera toxin co-administrated with the C. difficile S-layer precursor SlpA as antigen. After challenge, a significant decrease of C. difficile intestinal colonization was observed in immunized groups compared to the control group. Our results showed that C. difficile FliC could be used as adjuvant in mucosal vaccination strategy against C. difficile infections.
[Mh] Termos MeSH primário: Adjuvantes Imunológicos/farmacologia
Proteínas de Bactérias/imunologia
Vacinas Bacterianas/imunologia
Clostridium difficile/imunologia
Flagelina/metabolismo
Imunidade nas Mucosas/efeitos dos fármacos
[Mh] Termos MeSH secundário: Animais
Anticorpos Antibacterianos/imunologia
Contagem de Células
Clostridium difficile/efeitos dos fármacos
Clostridium difficile/metabolismo
Contagem de Colônia Microbiana
Enterocolite Pseudomembranosa/sangue
Enterocolite Pseudomembranosa/imunologia
Enterocolite Pseudomembranosa/microbiologia
Feminino
Imunidade/efeitos dos fármacos
Imunização
Imunoglobulina G/sangue
Mucosa Intestinal/efeitos dos fármacos
Mucosa Intestinal/imunologia
Mucosa Intestinal/microbiologia
Glicoproteínas de Membrana/imunologia
Camundongos Endogâmicos C57BL
Ovalbumina/imunologia
Reto/imunologia
Vacinação
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adjuvants, Immunologic); 0 (Antibodies, Bacterial); 0 (Bacterial Proteins); 0 (Bacterial Vaccines); 0 (Immunoglobulin G); 0 (Membrane Glycoproteins); 0 (S-layer proteins); 12777-81-0 (Flagellin); 9006-59-1 (Ovalbumin)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171219
[Lr] Data última revisão:
171219
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171128
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0187212


  9 / 6819 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28974444
[Au] Autor:Shi Y; Halperin SA; Lee SF
[Ad] Endereço:Department of Microbiology and Immunology, Dalhousie University, Halifax, Nova Scotia B3H 1X5, Canada; Canadian Center for Vaccinology, Dalhousie University, Nova Scotia Health Authority, Izaak Walton Killam Health Centre, Halifax, Nova Scotia B3K 6R8, Canada.
[Ti] Título:Expression, purification, and functional analysis of an antigen-targeting fusion protein composed of CD40 ligand and the C-terminal fragment of ovalbumin.
[So] Source:Protein Expr Purif;142:37-44, 2018 Feb.
[Is] ISSN:1096-0279
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Delivering antigen via molecules specifically targeting receptors on the surface of antigen-presenting cells is a strategy to improve immune responses. In this study, an antigen-targeting fusion protein (OVA-CD40LS) composed of the C-terminal fragment of ovalbumin and the extracellular domain of mouse CD40 ligand was constructed by genetic fusion. The OVA-CD40LS and the control OVA (rOVA) genes were cloned in Escherichia coli and over-expressed as insoluble proteins. The rOVA protein was purified from the insoluble fraction of E. coli cell lysate by nickel affinity chromatography and refolded by step-wise dialysis to give a yield of 11.8 mg/L of culture. The OVA-CD40LS was purified by a 'two-round' nickel affinity and on-column protein-refolding chromatography. The yield was 528 µg/L of culture. The purified OVA-CD40LS, but not the rOVA, was able to simulate the production of pro-inflammatory cytokines and up-regulate cell surface marker proteins in mouse bone marrow-derived dendritic cells. The purified OVA-CD40LS elicited a robust immune response when injected submucosally in the oral cavity of mice. Collectively, the results indicate that the OVA-CD40LS fusion protein was biologically active, functioning as an antigen-targeting protein.
[Mh] Termos MeSH primário: Ligante de CD40/imunologia
Células Dendríticas/efeitos dos fármacos
Imunidade nas Mucosas/efeitos dos fármacos
Ovalbumina/imunologia
Plasmídeos/química
Proteínas Recombinantes de Fusão/biossíntese
[Mh] Termos MeSH secundário: Animais
Anticorpos/sangue
Células da Medula Óssea/citologia
Células da Medula Óssea/efeitos dos fármacos
Células da Medula Óssea/imunologia
Ligante de CD40/genética
Clonagem Molecular
Células Dendríticas/citologia
Células Dendríticas/imunologia
Escherichia coli/genética
Escherichia coli/metabolismo
Feminino
Expressão Gênica
Imunização
Interleucina-6/biossíntese
Camundongos
Camundongos Endogâmicos BALB C
Mucosa Bucal/citologia
Mucosa Bucal/efeitos dos fármacos
Mucosa Bucal/imunologia
Ovalbumina/genética
Plasmídeos/metabolismo
Cultura Primária de Células
Proteínas Recombinantes de Fusão/administração & dosagem
Proteínas Recombinantes de Fusão/genética
Proteínas Recombinantes de Fusão/imunologia
Fator de Necrose Tumoral alfa/biossíntese
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies); 0 (Interleukin-6); 0 (Recombinant Fusion Proteins); 0 (Tumor Necrosis Factor-alpha); 0 (interleukin-6, mouse); 147205-72-9 (CD40 Ligand); 9006-59-1 (Ovalbumin)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171128
[Lr] Data última revisão:
171128
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171005
[St] Status:MEDLINE


  10 / 6819 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27773482
[Au] Autor:Bacher P; Heinrich F; Stervbo U; Nienen M; Vahldieck M; Iwert C; Vogt K; Kollet J; Babel N; Sawitzki B; Schwarz C; Bereswill S; Heimesaat MM; Heine G; Gadermaier G; Asam C; Assenmacher M; Kniemeyer O; Brakhage AA; Ferreira F; Wallner M; Worm M; Scheffold A
[Ad] Endereço:Department of Cellular Immunology, Clinic for Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, 10117 Berlin, Germany.
[Ti] Título:Regulatory T Cell Specificity Directs Tolerance versus Allergy against Aeroantigens in Humans.
[So] Source:Cell;167(4):1067-1078.e16, 2016 11 03.
[Is] ISSN:1097-4172
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:FOXP3+ regulatory T cells (Tregs) maintain tolerance against self-antigens and innocuous environmental antigens. However, it is still unknown whether Treg-mediated tolerance is antigen specific and how Treg specificity contributes to the selective loss of tolerance, as observed in human immunopathologies such as allergies. Here, we used antigen-reactive T cell enrichment to identify antigen-specific human Tregs. We demonstrate dominant Treg-mediated tolerance against particulate aeroallergens, such as pollen, house dust mites, and fungal spores. Surprisingly, we found no evidence of functional impairment of Treg responses in allergic donors. Rather, major allergenic proteins, known to rapidly dissociate from inhaled allergenic particles, have a generally reduced capability to generate Treg responses. Most strikingly, in individual allergic donors, Th2 cells and Tregs always target disparate proteins. Thus, our data highlight the importance of Treg antigen-specificity for tolerance in humans and identify antigen-specific escape from Treg control as an important mechanism enabling antigen-specific loss of tolerance in human allergy.
[Mh] Termos MeSH primário: Hipersensibilidade/imunologia
Imunidade nas Mucosas
Tolerância a Antígenos Próprios
Linfócitos T Reguladores/imunologia
[Mh] Termos MeSH secundário: Alérgenos/imunologia
Autoantígenos/imunologia
Seres Humanos
Memória Imunológica
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Allergens); 0 (Autoantigens)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:171127
[Lr] Data última revisão:
171127
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161105
[St] Status:MEDLINE



página 1 de 682 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde